Nuveen
XBI icon

Nuveen’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nuveen’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15K Buy
+205
New +$32.4K ﹤0.01% 4459
2025
Q2 		– Sell
-149,658
Closed -$12.1M – 3424
2025
Q1 		$12.1M Buy
149,658
+542
+0.4% +$48.4K ﹤0.01% 1434
2024
Q4 		$13.4M Buy
149,116
+39
+0% +$3.78K ﹤0.01% 1433
2024
Q3 		$14.7M Buy
149,077
+1,182
+0.8% +$116K ﹤0.01% 1380
2024
Q2 		$13.7M Sell
147,895
-58,005
-28% -$5.2M ﹤0.01% 1375
2024
Q1 		$19.5M Sell
205,900
-269
-0.1% -$25K 0.01% 1198
2023
Q4 		$18.4M Buy
206,169
+18,630
+10% +$1.38M 0.01% 1214
2023
Q3 		$13.7M Buy
187,539
+62
+0% +$4.95K ﹤0.01% 1286
2023
Q2 		$15.6M Sell
187,477
-132
-0.1% -$11K 0.01% 1243
2023
Q1 		$14.3M Buy
187,609
+34,817
+23% +$2.89M 0.01% 1256
2022
Q4 		$12.7M Buy
152,792
+99,163
+185% +$8.03M ﹤0.01% 1338
2022
Q3 		$4.25M Buy
+53,629
New +$4.52M ﹤0.01% 1995
2020
Q4 		– Sell
-39,006
Closed -$4.35M – 3372
2020
Q3 		$4.35M Sell
39,006
-8,903
-19% -$998K ﹤0.01% 1987
2020
Q2 		$5.36M Sell
47,909
-20,487
-30% -$2.02M ﹤0.01% 1856
2020
Q1 		$5.3M Buy
68,396
+39,253
+135% +$3.48M ﹤0.01% 1687
2019
Q4 		$2.77M Sell
29,143
-15,884
-35% -$1.37M ﹤0.01% 2287
2019
Q3 		$3.43M Sell
45,027
-29,284
-39% -$2.43M ﹤0.01% 2147
2019
Q2 		$6.52M Buy
74,311
+25,697
+53% +$2.19M ﹤0.01% 1845
2019
Q1 		$4.4M Buy
48,614
+21,470
+79% +$1.83M 0.02% 528
2018
Q4 		$1.95M Sell
27,144
-123,215
-82% -$9.9M 0.01% 622
2018
Q3 		$14.4M Buy
150,359
+2,674
+2% +$259K 0.08% 372
2018
Q2 		$14.1M Sell
147,685
-599
-0.4% -$55.1K 0.09% 328
2018
Q1 		$13M Buy
148,284
+18,069
+14% +$1.65M 0.08% 331
2017
Q4 		$11.1M Sell
130,215
-5,343
-4% -$448K 0.07% 370
2017
Q3 		$11.7M Buy
135,558
+13,961
+11% +$1.12M 0.08% 361
2017
Q2 		$9.38M Buy
+121,597
New +$8.62M 0.06% 422

Other funds holding XBI

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return
Employees Retirement System of Texas
Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return
Investure LLC
Investure LLC Charlottesville, Virginia $1.83B AUM 14.32% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Nuveen's XBI Position: Q3 2026 in Review

Nuveen opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 205 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #4459 among its holdings. This is a return to the name: Nuveen previously reported a position in XBI as recently as Q1 2025.

Nuveen first reported a position in XBI in Q2 2017 and has held it in 26 quarters since. The position peaked at $19.5M in Q1 2024. 583 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Nuveen held 205 shares of State Street SPDR S&P Biotech ETF worth $15K as of Q3 2026.
  • State Street SPDR S&P Biotech ETF was a new Nuveen position in Q3 2026.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4459 holding.
  • Nuveen first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 26 quarters since.
  • Nuveen's State Street SPDR S&P Biotech ETF position peaked at $19.5M in Q1 2024.
  • 583 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.